CVMP meeting highlights 3–5 November 2026

Authorisations and variations

The Committee adopted positive opinions for multiple marketing authorisations: Scovella (velagliflozin) for reduction of hyperinsulinaemia and laminitis risk in horses with Equine Metabolic Syndrome and the first product recommended under the limited market framework; Credelio Quattro (lotilaner/moxidectin/pyrantel/praziquantel) for simultaneous external and internal parasitic infestations in dogs; Laverdia (verdinexor) to increase time to progression in dogs with stage II–IV lymphoma in a home setting as a minor use/limited market product; Streptoporc for passive immunisation against Streptococcus suis genotype 1.1; and Nobivac PLUS DHPPi / Leptos for active immunisation of dogs from six weeks of age.

Product modifications and safety

Positive opinions were adopted for variations including Syvazul BTV 3 (ELISA potency test completion and duration-of-immunity study), Hepizovac (stability data to confirm 18‑month shelf life), Orbyk EHD (potency validation and 10‑hour in‑use shelf life), addition of "aggression" as a very rare adverse event for Zenrelia (ilunocitinib), and a new ear‑mite indication for Credelio (lotilaner).

Re-examinations, guidance and reports

The Committee recommended one‑year extensions of authorisations in exceptional circumstances for Vaxxinact H5 and Vaxxitek HVT+IBD+H5. It adopted the Fifth JIACRA report (incorporating environmental data and 2022–2024 trends) for publication on 10 December, and released VICH GL49(R2) for a six‑month public consultation until end‑April 2027. The revised VGVP Module: MI VeDDRA terms was also issued for public consultation.

Other items

The Committee adopted one scientific advice report for a biological product for horses, published outcomes of the monthly signal management process on the IRIS portal, and made several working‑party appointments including Jana Pantzke as vice‑chair of the 3Rs Working Party.